New use of angiotensin ii antagonists

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/4184 (2006.01) A61K 31/4178 (2006.01) A61K 31/4188 (2006.01) A61K 31/4196 (2006.01) A61K 31/437 (2006.01) A61K 31/506 (2006.01) A61K 31/519 (2006.01) A61P 9/12 (2006.01) A61P 25/06 (2006.01)

Patent

CA 2411553

The present invention relates to the use of an angiotensin II type 1 receptor antagonist of the general formula (I) in the manufacture of a medicament for the prophylactic and/or therapeutic treatment of a vascular headache condition such as migraine, in a subject suffering from, or susceptible to, such a vascular headache condition. A further aspect of the invention is a pharmaceutical formulation useful in any one of said vascular headache conditions, as well as a method of treatment thereof.

La présente invention concerne l'utilisation de l'antagoniste du récepteur de l'angiotensine II type 1 selon la formule générale (I) pour produire un médicament permettant de traiter et/ou de prévenir un état de céphalée vasculaire telle qu'une migraine, chez un sujet souffrant ou susceptible de souffrir d'un tel état de céphalée vasculaire. L'invention concerne également une formulation pharmaceutique utile quel que soit l'état de céphalée vasculaire, ainsi qu'un procédé de traitement correspondant.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

New use of angiotensin ii antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with New use of angiotensin ii antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and New use of angiotensin ii antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1582361

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.